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Suffolk Vascular Unit, The Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk IP4 SPD, UKObjective. To develop an evidence-based protocol for the management of iliofemoral deep vein thrombosis (IDVT) in
childhood.
Methods. A search of the literature was undertaken. All publications pertaining to IDVT in childhood were analysed and
then categorised according to their level of evidence. Recommendations were then made on the basis of this.
Results. The commonest presenting symptoms were pain and swelling in the affected limb (evidence level II). Predisposing
risk factors of special significance in children included the recent use of a venous access device, malignancy, prothrombotic
disorders, infection, surgery and congenital venous anomalies (evidence level II). The most frequently described imaging
modalities were B-mode ultrasonography, duplex, venography, and helical CT (evidence level III). The mainstay of treatment
was anticoagulation with LMWH alone or followed by warfarin (evidence level I). Early clot removal through catheter-
directed thrombolysis or surgical thrombectomy has been shown to be beneficial (evidence level II/III). There is little evidence
for the benefit of early mobilisation and compression therapy in childhood.
Conclusion. Level I evidence relating to IDVT in childhood is sparse. The possibility of IDVT should be considered when
examining a child with a swollen and painful limb. Imaging should be with duplex ultrasound, followed by spiral CT to
include assessment of the IVC. A thrombophilia screen should be taken prior to anticoagulation with LMWH (and warfarin).
Thrombolysis should be considered in cases of extensive IDVT.Keywords: Paediatric; Deep vein thrombosis; Management; Anticoagulation; Thrombolysis; Thrombectomy.Introduction
The estimated incidence of symptomatic venous
thromboembolic disease (VTE) in children is
5.3/10,000 (0.05%) hospital admissions versus 2.5–5%
for adults.1–10 The occurrence of VTE in childhood has
a bimodal distribution. The first peak is in the neonatal
period (0–28 days) and is thought possibly to be due to
the lower concentrations of antithrombin, heparin
cofactor II and protein C along with a reduced
fibrinolytic capacity, thus resulting in a prothrombotic
state. The incidence then decreases significantly after
the first year of life, with the second peak during
puberty and on into adolescence, associated with
reduced fibrinolytic activity.11 VTE, does occur at all
ages (as demonstrated in Section 2), has many well-
recognised risk factors and others that are rarely
considered. In this paper, we consider the evidence
behind those risk factors that should be sought, theing author. R.E. Brightwell, BM, MRCS(Eng), Regional
, St Mary’s Hospital, Praed Street, Paddington, London
.
: r.brightwell@imperial.ac.uk
0667 + 12 $35.00/0 q 2006 Elsevier Ltd. All rights reserinvestigations best employed and treatment options in
the management of iliofemoral deep vein thrombosis
(IDVT) in the paediatric patient.Case Study
A 7-year-old schoolboy presented with a 4-day history of
right-sided hip and groin pain associated with a limp on
that side. There was no prodromal illness of note. He had
been born by normal vaginal delivery at 42 weeks and
had no history of admission to Special Care Baby Unit or
central venous catheterisation. Since 3 years of age, he
was noted to have some autistic features and thus
continues to attend a special needs school. On examin-
ation he was well with no features of systemic disease.
Since, admission his right leg had become swollen (mid-
thigh circumference 2.5 cm greater than left) with
evidence of superficial venous hypertension (Fig. 1). It
was also noted that the right testicle was absent.
Examination of the hip and knee was normal. A
diagnosis of proximal deep vein thrombosis was
suspected and confirmed by compression duplex scan..Eur J Vasc Endovasc Surg 31, 667–678 (2006)
doi:10.1016/j.ejvs.2005.11.028, available online at http://www.sciencedirect.com onved.
Fig. 1. Patient with swollen right leg and signs of superficial
venous hypertension.
R. E. Brightwell and I. S. Osman668A thrombophilia screen was sent before commencing
the patient on subcutaneous low molecular weight
heparin (LMWH) for 2 weeks, prior to commencing
warfarin. He was found to be heterozygous for factor V
Leiden mutation. Compression therapy with grade I
compression stockings was commenced and multi-slice
CTscanning of the abdomen and pelvis was performed.
This scan demonstrated an absent infra-renal inferior
vena cava with the pelvic and lower limb veins draining
through grossly dilated spinal and lumbar veins (Fig. 2).
There was no abnormality of the solid abdominal
organs. Anticoagulation with warfarin shall continue
indefinitely.Fig. 2. CT image (unenhanced) showing absent infra-renal
IVC.
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An electronic search of the literature was undertaken
using search terms of ‘thrombosis’, ‘paediatric’,
‘pediatric’, ‘childhood’, ‘venous’, ‘diagnosis’,
‘therapy’, and ‘management’. All publications pertain-
ing to the management of IDVT in childhood were
analysed and then categorised according to their level
of evidence. Recommendations were then made on the
basis of this.Systemic VTE in the Paediatric Patient
The majority of VTE within the first year of life is
associated with central venous access devices.8–10,12,13
The femoral vein is rarely used for central venous
access in the neonate (the majority of catheters were
inserted via an umbilical vein or the upper venous
system) so IDVT is rarely seen in this population.
However, there have been reports of spontaneous
thromboses in the visceral veins of neonates, but these
have been linked to factors such as sepsis, dehy-
dration, perinatal hypoxia, or maternal diabetes.14
While an age greater than 1 year seems to be
protective via such postulated mechanisms as a
reduced capacity to produce thrombin,15,16 increased
capacity of alpha-2 macroglobulin to inhibit throm-
bin,17 and enhanced antithrombotic potential of the
vessel wall,18,19 there are increasing numbers of
children older than this developing VTE as secondary
complications to other underlying disorders. Approxi-
mately 95% of episodes of VTE in childhood have an
underlying, serious condition as an aetiological factor
causing the thrombosis. These conditions include
malignancy, trauma, surgery, congenital heart disease
and other malformations of the vascular system, renal
disease and autoimmune diseases such as systemic
lupus erythematosus (SLE).8,20–22 The important
acquired and congenital risk factors associated with
VTE are shown in Tables 1 and 2, respectively.
The role of congenital prothrombotic states in the
aetiology of VTE remains controversial. There is good
evidence that the defects affecting the physiological
anticoagulant system (i.e. factor V Leiden mutation,
factor II variant G20210A, and deficiencies in proteins
C and S, and antithrombin) can play a causal role in
thrombotic events.23,24 Metabolic diseases such as
hyperhomocysteinaemia due to the homozygous
methylenetetrahydrofolate reductase (MTHFR) poly-
morphism C677T, homozygous homocystinuria, and
increased concentrations of lipoprotein (a) have been
shown to increase the risk of both arterial and venous
thromboembolism.23–28
Table 1. Acquired risk factors associated with paediatric VTE49
Perinatal diseases Birth hypoxia/asphyxia
Respiratory distress syndrome
Neonatal sepsis
Diabetic mother
Dehydration
Necrotizing enterocolitis (NEC)
Polycythaemia
Congenital nephritic syndrome
Iatrogenic cause Central venous access devices
Surgery
Immobilisation
Traction/plaster cast
Extracorporeal membrane oxygenation
(ECMO)
Acute illnesses Trauma
Sepsis
Dehydration
Nephrotic syndrome
Acute lymphoblastic leukaemia
Acute rheumatic diseases
Chronic illnesses Malignancy
Renal diseases
Cardiac malformation
Chronic rheumatic/autoimmune diseases
Lupus anticoagulant
SLE
Antiphospholipid antibody syndrome
Behc¸et’s disease
Diabetes mellitus
Inflammatory bowel disease
Haematological disease
Thalassaemia
Chemotherapy/
drugs
Prednisolone
Oral contraceptives
L-aspariginase
Heparins
Coagulation factor concentrates
Smoking
Table 2. Inherited and congenital risk factors for paediatric VTE49
Haematological Common
Factor V G1691A gene mutation
Factor II G20210A gene mutation
Increased apolipoprotein (a)
Homozygous C677T polymorphism in the
MTHFR gene
Activated protein C resistance
Rare
Protein C deficiency
Protein S deficiency
Antithrombin deficiency
Hyperhomocysteinaemia
Very rare
Dysfibrinogenaemia
Plasminogenaemia
Homozygous homocystinuria
Probably inherited
Increased factor VIIIC, IX, or fibrinogen
Decreased levels of factor XII
Anatomical Cardiac
Venous
Anomalous venous anatomy
Absent IVC
Structural
Cervical rib
Paediatric Iliofemoral DVT 669VTE in children (and adults) is a multifactorial
condition. There is now level II evidence that multiple
haemostatic prothrombotic defects or the association
of these risk factors with environmental or clinical
situations greatly increases the risk of VTE.29,30 The
relative risk of recurrent episodes of VTE is also
significant and increases with the number of inherited
gene defects. It has been shown that there is a 4.6-fold
increased risk of recurrent VTE in children with a first
spontaneous thrombosis and a single prothrombotic
defect, and a documented 24-fold increased risk in
those with multiple defects.27Central Venous Catheter Related VTE
Central venous catheters (CVC) are placed for short-
term use. They are used mostly in intensive care
settings for fluid management, haemodialysis, and
drug administration or for long-term supportive care
for children requiring total parenteral nutrition (TPN)
or chemotherapy for malignant disease. CVC-related
VTE does carry a significant morbidity, including
pulmonary embolus (PE)31,32 and post-thrombotic
syndrome (PTS).33 CVC-related VTE has been divided
into three types; clots at the tips of the CVC that impair
the withdrawal of blood or infusion, fibrin sleeves that
are not adherent to the vessel wall but occlude the
catheter, and CVC-related VTE that is adherent to the
vessel wall, can cause complete or partial occlusion
and is, therefore, the most clinically significant.34
While in most circumstances such catheters are placed
in the jugular or subclavian vein, in the older child that
is critically ill, or a younger child with a chronic
condition where alternative access sites have been
exhausted, the femoral vein can provide central
venous access. Femoral CVC-related VTE is, therefore,
an important clinical entity and needs to be considered
when assessing a child with IDVT (level C
recommendation).Clinical Presentation
The clinical syndrome associated with IDVT can
present to a number of specialists; most frequently
paediatricians, but also vascular surgeons, orthopae-
dic surgeons (as in our case) and others. A multi-
disciplinary approach is mandatory, and will certainly
require input from radiology, haematology and also
other professions allied to medicine such as
physiotherapy.
Deep vein thrombosis (DVT) occurs in the upper
venous system in 60% of children, mostly being CVC-Eur J Vasc Endovasc Surg Vol 31, June 2006
Table 3. Signs and symptoms of acute IDVT
Symptoms None
Pain
Immobility
Reduced range of motion
Swelling
Shoe(s) not fitting
Jewellery not fitting
Underlying disease
Complication
PE
Phlegmasia cerula dolens
Signs Swelling
Tenderness over affected vessels
Venous hypertension
Discoloured limb
Visible superficial veins
Underlying disease
Complication (i.e. PE)
Chest pain
Shortness of breath
Haemoptysis
Cardiac arrhythmia
R. E. Brightwell and I. S. Osman670related.10 Non-CVC-related DVT that is symptomatic
occurs most frequently in the lower extremities.35
Those DVTs affecting the proximal iliac and femoral
vessels are the most clinically important, given the
higher incidence of PE amongst this patient group and
potential seriousness of subsequent PTS. There is a
myriad of symptoms associated with IDVT and these
are summarised in Table 3. The commonest presenting
symptoms found in the literature were pain and
swelling in the affected limb (evidence level III). The
clinician must maintain a high index of suspicion of
VTE when managing a child who presents with these
features.Diagnosis of IDVT
While there has been a study to assess the diagnostic
investigation that best determines that location of
CVC-related VTE in the upper venous system,36,37
there are currently no studies determining the
sensitivity and specificity of diagnostic testing forTable 4. Recommended screening and re-screening for prothromboti
Protein based assays at onset DNA based ass
APC-resistance Factor V G1691
Protein C activity Factor II G2021
Free protein S antigen MTHFR C677T
Antithrombin activity Other polymorp
Fibrinogen
Plasminogen
Factor VIIIC, factor XII
Lipoprotein (a)
Fasting homocysteine
Antiphospholipid/anticardiolipin IgM/IgG
Eur J Vasc Endovasc Surg Vol 31, June 2006lower venous system CVC and non-CVC-related VTE
in children. The best that can be gained is level III
evidence on which one can make the level C
recommendation of compression B-mode ultrasono-
graphy and duplex ultrasonography as screening
tests. Venography remains the ‘gold standard’ test,
and helical CT (with contrast) or magnetic resonance
venography are useful to provide anatomical/struc-
tural data on the venous system (and other areas of
interest) as well as some information about the extent
of thrombus in those parts of the venous system not
visualised by ultrasound (such as the pulmonary
vasculature if suspicious of PE).38 It is recommended
by the authors that a cross-sectional modality is used
routinely in conjunction with ultrasound and/or
venography due to the limited information that the
latter diagnostic methods give about surrounding
structures.Management Once IDVT is Confirmed
Alongside definitive treatment (either anticoagulation
or thrombus removal by whatever mechanism), blood
must be drawn for screening of pro-thrombotic risk
factors as described in Table 4. It is important to stress
that such testing should follow a logical, step-wise
procedure and should be supervised by a haematol-
ogist (Fig. 3). It is worth pointing out at this stage that
‘normal’ values for these proteins and DNA assays
vary for different ethnic groups, and even geographi-
cally within the same group.39–42
Level I and II evidence exists to support the
screening of patients in a specialist anticoagulation
clinic for thrombophilic defects.12,14,25–27,43–48 There is
also evidence from a study in 2001 that when
thrombosis occurs in a paediatric patient in the
absence of an underlying cause, the risk of recurrent
VTE is also sufficiently high to justify such detailed
investigation and analysis.27
Protein-based assays can be affected by the acute
thrombotic episode and, therefore, plasma samplesc risk factors
ays at onset Protein based assays: repeated testing
A Protein C activity
0A Free protein S antigen
Antithrombin activity
hisms Fibrinogen
Plasminogen
Factor VIIIC, factor XII
Lipoprotein (a)
Fasting homocysteine
Antiphospholipid/anticardiolipin IgM/IgG
Fig. 3. Management decisions in paediatric IDVT.
Paediatric Iliofemoral DVT 671should be obtained at least 3–6 months after the initial
episode (recommendation level B). Oral anticoagu-
lants may also influence protein-assays, so it is
recommended that samples are drawn 14–30 days
after cessation of oral anticoagulants. The situation
with parenteral anticoagulants (unfractionated
heparin and LMWH) is less clear, and to maintain
the quality of results it is suggested that samples are
taken when the patient is not receiving these drugs.
DNA assays are affected neither by the acute
thrombotic episode nor the administration of throm-
bolytic or anticoagulant agents, and can, therefore, be
performed at any point after the VTE episode
(evidence level III, recommendation level C).49Treatment Options
The rarity of the condition has meant that there have
been no large-scale, prospective trials conducted.
Treatment options include anticoagulation, systemic
thrombolysis (bolus and/or infusion), local/catheter-
directed thrombolysis and thrombectomy. Analysis ofthe literature would suggest that treatment strategies
vary greatly between, and even within institutions.
While the general approach to paediatric thrombo-
sis is the same as adults, the differences in underlying
aetiology, age related variations in the clotting system
and technical differences may affect the choice of
treatment method.Antithrombotic therapy in childrenHeparin
Unfractionated heparin (UFH) remains a commonly
used anticoagulant in paediatric patients. A tertiary
referral centre for paediatrics reported up to 15% of
inpatients were exposed to UFH each day.50
Mechanism of action. The main anticoagulant activi-
ties of heparin are mediated by the catalysis of
antithrombin (AT) and can be impaired by low plasma
levels of this protein. Physiologically low levels of AT
(!0.30 U/ml) are found from birth to w3 months of
age,51–53 and can be even lower in acute disease
states.53,54 Heparin inactivates specific coagulationEur J Vasc Endovasc Surg Vol 31, June 2006
Table 5. Protocol for administration and adjustment of systemic (IV) unfractionated heparin in children58
Stage Description aPPT (s) Bolus (U/kg) Stop infusion
(min)
Rate change
(%)
Repeat aPPT
I Loading dose 75 IV over
10 min
II Initial maintenance dose
Infants!1 year 28/h
ChildrenO1 year 20/h
III Adjustment* !50 50 0 C10% 4 h
50–59 0 0 C10% 4 h
60–85 0 0 0 Next day
86–95 0 0 K10% 4 h
96–120 0 30 K10% 4 h
O120 0 60 K15% 4 h
IV Obtain blood for aPTT, check 4 h after
heparin loading dose and 4 h after every
change in infusion rate
V When apt values are in therapeutic
range, perform daily FBC and aPTT
measurement
* Heparin adjusted to maintain aPTT at 60–85 s, assuming that this reflects an anti-FXa level of 0.35–0.70.
R. E. Brightwell and I. S. Osman672enzymes (in particular thrombin) through its action
on AT.55
Therapeutic range. The therapeutic range for the
treatment of VTE in adults is an aPTTcorresponding to
a heparin volume by protamine titration of 0.2–
0.4 U/ml or an anti-FXa level of 0.35–0.7 U/ml.56
Unfortunately, aPTT ranges are universally calculated
using adult plasma and extrapolating these ranges to a
paediatric patient group is of unknown validity. Also
children have a higher baseline aPTT, so any increase
in this value represents a reduced relative increment
when compared to similar changes in the adult
population. However, aPTT values in paediatric
patients correctly predict therapeutic heparin doses
in about 70% of cases.57
Dose and monitoring. The dose of heparin required in
paediatric patients to achieve adult therapeutic aPTT
values has been assessed in a prospective cohort study
using a weight-based normogram. Bolus doses of 75–
100 U/kg result in therapeutic aPTT values in 90% of
children. Maintenance doses are age-dependent and
can be seen in Table 5. As in adults, dose adjustment of
IV UFH in paediatric patients is challenging, but a
validated method is demonstrated also in Table 5.Low molecular weight heparins
LMWHs have quickly become the treatment of choice
for paediatric VTE, despite the lack of data supporting
their efficacy in these indications. Advantages of these
drugs include a reduced need for monitoring
(especially useful in a child) and a reduced incidence
of side effects associated with UFH such as heparin-
induced thrombocytopaenia (HIT), osteoporosis and
drug interaction. Perhaps due to altered plasma
binding characteristics, weight-adjusted doses appearEur J Vasc Endovasc Surg Vol 31, June 2006to be less predictable when compared to adult
groups.55,58
Mechanism of action. At similar anti-FXa concen-
trations, UFH inhibits free-thrombin generation to a
greater degree than does LMWH in neonates,
children and adults. Studies in vitro show thrombin
generation is similar in adults and children at the
same concentration of LMWH. Further work demon-
strated at a LMWH concentration of 0.25 U/ml
thrombin generation was delayed and reduced by
approximately half in newborns compared to adults.
The observed differences were matched by reciprocal
reductions in the rates of prothrombin
consumption.59
Therapeutic range. In a situation similar to UFH,
doses of LMWH have been extrapolated from adult
studies, and are centred on anti-FXa levels. Evidence
would suggest that anti-FXa levels of 0.5–1.0 U/ml
measured in a sample drawn 4–6 h post-subcutaneous
injection indicates a therapeutic dose of LMWH.
Dosing guidelines are shown in Table 6.
Monitoring. Once a therapeutic dose has been
achieved, the need for ongoing monitoring has yet to
be established in a paediatric population.Warfarin and other vitamin K antagonists (VKA)
These drugs function through inhibiting hepatic
production of the vitamin K-dependent factors in the
clotting cascade (II, VII, IX and X). In neonate, these
clotting factors are decreased to levels similar to adults
on therapeutic doses of warfarin. The problems of
VKA administration in newborns, and some older
children, are manyfold. Formula milk contains high
levels of vitamin K (to prevent haemorrhagic disease
of the newborn) and as such babies fed this way are
Table 6. Dosing guidelines for LMWH in treating paediatric
patients with VTE58
Drug Initial treatment
dose
Initial prophylactic
dose
Enoxaparin
Age-dependent dose (mg/kg b.d.)
!2months 1.5 0.75
O2 months 1.0 0.5
Dalteparin
All age paediatric
dose (U/kg o.d.)
129G43 92G52
Tinzaparin
Age-dependent dose (U/kg)
0–2 months 275
2–12 months 250
1–5 years 240
5–10 years 200
10–16 years 275
Reviparin
Weight-dependent dose (U/kg b.d.)
!5 kg 150 50
O5 kg 100 30
Paediatric Iliofemoral DVT 673relatively VKA-resistant. Conversely, breast
milk contains low concentrations of vitamin K,
and subsequently breast-fed babies are VKA
sensitive.60,61
VKAs are also only available in tablet form, and
while they can be dissolved in water, there are no
validated safety and efficacy data for this mode of
administration. Monitoring is perhaps the most
important and challenging issue. Frequent assessment
of the INR is required, due to changes in diet,
medications and plasma concentrations of the vita-
min-K dependent factors. Venous access soon becomes
troublesome in this sub-group of patients.
Therapeutic range. Current therapeutic INR ranges
for children are extrapolated from adult studies
because no clinical trial has assessed the optimal INR
range for paediatric patients based on clinical indi-
cation or outcome. A protocol for dosing warfarin (and
the other VKAs) is shown in Table 7.Table 7. Protocol for dosing paediatric patients with VKA—to maint
Stage INR Action
I
Day 1 1.0–1.3 0.2 mg/kg
II
Days 2–4 1.1–1.3 Repeat da
1.4–1.9 50% of da
2.0–3.0 50% of da
3.1–3.5 25% of da
O3.5 Hold dosi
III
Maintenance 1.1–1.4 Increase b
1.5–1.9 Increase b
2.0–3.0 No chang
3.1–3.5 Decrease
O3.5 Hold dosiThrombolytic agents
The evolution of treatment for intra-arterial thrombo-
sis in adult populations, especially during myocardial
infarction, saw the arrival and subsequent develop-
ment of a range of ‘clot-busting’ drugs. These novel
treatments then enjoyed a wider range of clinical
applications including treatment of VTE. The route of
administration has also been studied in the adult
setting, with the options being systemic or local/cath-
eter-directed thrombolysis (CDT). While one study
supports the use of CDT in adult occlusive iliofemoral
DVT, there are no studies that compare the efficacy,
safety, or cost of different thrombolytic agents in
children.
Mechanism of action. The actions of thrombolytic
drugs are mediated by converting endogenous plas-
minogen to plasmin. At birth there are decreased
levels of plasminogen (about 50% adult values, or
21 mg/100 ml)51,52 which slows the production of
plasmin62 and thus reduces the thrombolytic effect of
streptokinase (SK), urokinase (UK), and tissue plas-
minogen activator (tPA).63
tPA is the agent of choice in the paediatric setting.
The reasons include improved clot lysis in an in vitro
study when compared with SK and UK, lower
immunogenecity, greater fibrin specificity and, histori-
cally, less (theoretical) risk of virus transmission.64,65
tPA is more expensive than other thrombolytic agents
and no clinical trial has supported the in vitro data
suggesting enhanced clot lysis over and above SK and
UK. tPA has, perhaps, the strongest evidence-base in
the current literature, although there have been
institutional reports of experience using both SK and
UK. The optimal use, dosage, efficacy, and bleeding
toxicity of tPA thrombolysis in children are unknown.
Currently, anticoagulation using UFH or LMWH
constitutes standard therapy for children with throm-
bosis.10 However, paediatric haematologists areain an INR 2–358
orally
y 1 loading dose
y 1 loading dose
y 1 loading dose
y 1 loading dose
ng until INR!3.5, then restart according to stage III guidelines
y 20% of dose
y 10% of dose
e
by 10% of dose
ng until INR!3.5, then restart at 20% less than last dose
Eur J Vasc Endovasc Surg Vol 31, June 2006
R. E. Brightwell and I. S. Osman674regularly asked about the use of tPA in a growing
number of children who present with a wide variety of
thrombi. Interest in tPA is due to the recognition that
successful thrombolysis is associated with more rapid
and complete restoration of blood flow and less tissue
infarction.66 Thrombolytic therapy has been shown to
be more efficacious than anticoagulation alone in
adults with pulmonary embolism67 and acute coron-
ary thrombosis68 and for prevention of post-thrombo-
tic syndrome (PTS) secondary to IDVT.69 Children
exhibit low rates of death, pulmonary embolism,
thrombus propagation, thrombus recurrence, or bleed-
ing toxicity with anticoagulant therapy. PTS, a clinical
spectrum of swelling, pain, skin changes, and stasis
ulcers that occurs as a sequela to obstructed venous
flow, has been reported in 10–20% (and in one series
60%) of children with venous thrombosis.8,9,70,71
Dose and route of administration. There is a large
variation in reported tPA doses in children, with many
recommendations being transferred from the treat-
ment of arterial thrombosis. In the paediatric popu-
lation, the local dose of tPA has varied from 0.01 to
0.5 mg/kg/h and infusion times from a few hours to
30 days.
A prospective study using 0.5 mg/kg/h systemic
tPA for 6 h concurrently with heparin (10 U/kg/h)
and FFP supplementation (to augment its effects) prior
to tPA infusion reported complete clot lysis in 13 of 20
patients (65%) [arterial thrombosis, 12 patients; venous
thrombosis, one patient], partial resolution in four
patients (20%) [arterial thrombosis, one patient;
venous thrombosis, three patients], and no response
in three patients (15%) [arterial thrombosis, one
patient; venous thrombosis, two patients].72 Another
study used a dose of 0.5 mg/kg/h for the first hour
followed by 0.25 mg/kg/h until complete resolution
occurred or the infusion was complicated by bleeding.Table 8. A guide to thrombolytic therapy for paediatric patients58
Treatment Single-lumen CVC Double-l
Local instillation tPA
!10 kg 0.5 mg diluted in 0.9% NaCl to
required volume to fill line
0.5 mg p
line; trea
O10 kg 1.0 mg in 1.0 ml 0.9% NaCl; use
amount required to fill volume of
line to maximum of 2 mlZ2 mg
1.0 mg/m
maximu
a time
Treatment Loading dose
Systemic thrombolytic therapy
Urokinase 4400 U/kg
Streptokinase 2000 U/kg
Tissue plasminogen
activator (tPA)
None
Heparin should be commenced during, or immediately after completi
thrombin clotting time; PT, prothrombin time; FBC, full blood count.
Eur J Vasc Endovasc Surg Vol 31, June 2006Complete clot lysis was achieved in 16 of 17 patients
within 4–11 h.73 Wang et al. performed a study looking
at low-dose administration of tPA. Thirty-five children
were treated with either standard or low-dose
infusions of tPA.74 Results were complete thrombo-
lysis of 28 of 29 (97%) acute thrombi, while all six
chronic thrombi had a partial response. In contrast to
the recommended adult-derived dosages of 0.1–
0.5 mg/kg/h, the authors found that initial doses of
less than 0.01 mg/kg/h were effective in 12 of 17
patients with acute thrombosis. Neonates required
0.06 mg/kg/h. Major bleeding occurred in only one
extremely preterm infant. Minor bleeding, primarily
oozing at intravenous sites, occurred in 27% of
children during tPA infusions. Prophylactic UFH or
LMWH was infused concomitant with tPA in 42% of
the children and did not increase the risk of bleeding.
No data exist comparing the outcome of local and
systemic thrombolytic therapy in paediatric patients
making it impossible to suggest that there is an
advantage in either when treating children with
IDVT.75 There is also a theoretical risk that the small
vessel size in children may increase the risk of local
vessel injury with new thrombus subsequently form-
ing. In CVC-related VTE local therapy it would seem
most appropriate if the thrombolytic agent was
delivered via the catheter already in situ. There are
no reports of pulse-spray CDT in children.58 A guide to
doses of thrombolytic agent is shown in Table 8.
Adverse events. Technical problems with catheter
positioning (secondary to thrombus location and
patient size), vessel rupture, and local and distant
bleeding are potential complications of this pro-
cedure.76 A recent review of the literature determined
that bleeding complications requiring packed red cell
transfusions occur in 20% of children receiving tPA
thrombolysis.77 Weiner et al. reported intracranialumen CVC SC port
er lumen diluted in 0.9% NaCl to fill volume of
t one lumen at a time
0.5 mg diluted
with 0.9% NaCl to
3 ml
l; use amount required to fill volume of line to
m of 2 mlZ2 mg per lumen; treat one lumen at
2.0 mg diluted
with 0.9% NaCl to
3 ml
Maintenance dose Monitoring
4400 U/kg/h for 6–12 h Fibrinogen, TCT, PT, aPTT, FBC
2000 U/kg/h for 6–12 h Fibrinogen, TCT, PT, aPTT, FBC
0.1–0.6 mg/kg/h for 6 h Fibrinogen, TCT, PT, aPTT, FBC
ng thrombolytic therapy. A loading dose may be omitted. TCT,
Paediatric Iliofemoral DVT 675haemorrhage in two of seven neonates receiving tPA.78
A perception of increased tPA-associated bleeding has
limited the use of thrombolysis in children, and a
recent report with standard doses (0.5 mg/kg/h
average dose) also revealed significant bleeding
complications.65 Due to the inherent risk of thrombo-
lytic agents, anticoagulation alone should be con-
sidered for cases of thrombosis with non-urgent
sequelae.Thrombectomy and other surgical therapies
Surgical thrombectomy is rarely used as treatment in
children. The common situations in which thrombect-
omy is reported include IVC thrombosis associated
with intra-vascular extension of Wilm tumour, acute
thrombosis of Blalock–Taussig shunts, life-threatening
intra-cardiac thrombosis immediately after complex
cardiac surgery, prosthetic valve thrombosis, and
peripheral arterial thrombosis secondary to vascular
access in neonates. While there are no guidelines on
the use of surgical thrombectomy (specifically in
IDVT) there is consensus that in many situations the
risk of VTE recurrence secondary to vascular damage
remains high. The risk/benefit balance must be
considered on each case’s merits: where there is
threatened loss of life or limb surgical intervention
may be justified.58Table 9. Management decisions in paediatric IDVT: evidence and re
Management step
Clinical presentation
History/signs of painful, swollen limb with signs of superficial veno
distension
Imaging of thrombosis
USS/duplex as screening tool in upper limb
USS/duplex as screening tool in lower limb
Lineogram/venogram
CT/MR venogram
Diagnosis of underlying thrombophilia
Full prothrombotic screen by specialist laboratory at first presentatio
Diagnosis of underlying venous/structural anomaly
CT
MR
Use of heparins for 5–10 days for simple DVT
UFH
LMWH
Use of heparins for prolonged period for extensive DVT
UFH
LMWH
Six month administration of warfarin/VKA in first VTE
Thrombolysis
Should not be used routinely
Vena cava filter device
If patient at high risk of PE (i.e. contraindication to anticoagulation, P
full anticoagulation, extensive/proximal DVT)Several different percutaneous methods of throm-
bus removal are available and use a variety of
devices. These include direct aspiration (using
suction or hydrolytic action) and mechanical dis-
ruption (with spinning blades).79 Some investigators
are also assessing the possibility of clot lysis using
ultrasound.80 Depending on its mode of action the
catheter aspirates, macerates or fragments the
thrombus as it is advanced through the vessel.
Residual thrombus may be treated with low-dose,
short duration thrombolysis.81 As thrombectomy
will only clear large vessels thrombolysis may be
required to clear smaller vessels and restore tissue-
level perfusion.79 There is no study-derived evi-
dence to support the use of any of these devices in
children.Vena cava filter device
While the authors realise that this is not a direct
treatment for IDVT, it may prove a useful adjunct. IVC
(or less commonly SVC) filters may be placed in
patients who are at high risk of PE. The filters, of many
different designs, essentially act as a trap mechanism
for thrombus fragments travelling in the vena cava
that would otherwise embolise to the lung. Indications
for use would include patients in whom anticoagula-
tion or thrombolysis is too high risk (e.g. prior intra-commendation levels
Evidence level Recommendation
level
us III C
Ib A
III C
Ib A
3 C
n I/II B
III C
III C
I A
I A
I B
I B
II C
II C
E on III C
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R. E. Brightwell and I. S. Osman676ventricular haemorrhage) or have had break through
PE when fully anticoagulated.
There is limited experience in the use of filters in
children, with only a few case reports discussing
placement and follow-up.82–84 Many technical ques-
tions remain unanswered with regard to device
selection, duration of placement and overall safety
and efficacy. It is the most experimental of all those
therapies in children discussed here, and does carry
some associated morbidity. Complications include
migration, vessel perforation and thrombosis.
A summary of the management steps in treating a
child with acute IDVT, with evidence and recommen-
dation levels, is illustrated in Table 9.Conclusion
Level I evidence relating specifically to the treatment
of IDVT in children is sparse, with current practice a
result of extrapolating from adult medicine or an
institution’s or individual clinician’s preference. With
more episodes of paediatric VTE occurring and being
recognised, there is a need for greater consensus and
basic treatment guidelines.
Multiple factors, both genetic and acquired, con-
tribute to thrombosis in children. It appears that
children who are heterozygous for one or more risk
factor or who have an acquired defect (either
haematological or structural) are at an increased risk
of VTE. Both the coagulation system and venous
anatomy must be examined using techniques that
have been discussed in this paper.
The first-line treatment of IDVT is UFH or LMWH
to prevent extension, followed by long-term antic-
oagulation with a VKA to prevent recurrence. Early
experience suggests tPA thrombolysis may be safe and
effective in children with IDVT, if the diagnosis and
treatment is instituted within 14 days of the event.
After this period, experience in adult medicine at least,
has shown that the risk/benefit ratio favours con-
servative therapy.
As awareness of IDVT and other venous throm-
boembolic diseases grows, it may be possible to create
prospective, international registries or randomized
studies that will enable us to make stronger evidence-
based treatment recommendations.References
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